Journal of Pharmacy and Pharmaceutical Sciences最新文献

筛选
英文 中文
Development of a dry powder formulation for pulmonary delivery of azithromycin-loaded nanoparticles. 开发一种干粉制剂,用于向肺部输送阿奇霉素纳米颗粒。
IF 2.9 4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2024-10-14 eCollection Date: 2024-01-01 DOI: 10.3389/jpps.2024.13635
Alison Tatiana Madrid Sani, Khellida Loiane V Ramos-Rocha, Michelle Alvares Sarcinelli, Marcelo Henrique da Cunha Chaves, Helvécio Vinícius Antunes Rocha, Patrícia Léo, Natália Neto Pereira Cerize, Maria Helena Ambrosio Zanin, Valker Araujo Feitosa, Carlota de Oliveira Rangel-Yagui
{"title":"Development of a dry powder formulation for pulmonary delivery of azithromycin-loaded nanoparticles.","authors":"Alison Tatiana Madrid Sani, Khellida Loiane V Ramos-Rocha, Michelle Alvares Sarcinelli, Marcelo Henrique da Cunha Chaves, Helvécio Vinícius Antunes Rocha, Patrícia Léo, Natália Neto Pereira Cerize, Maria Helena Ambrosio Zanin, Valker Araujo Feitosa, Carlota de Oliveira Rangel-Yagui","doi":"10.3389/jpps.2024.13635","DOIUrl":"10.3389/jpps.2024.13635","url":null,"abstract":"<p><p>The COVID-19 pandemic has raised concern regarding respiratory system diseases and oral inhalation stands out as an attractive non-invasive route of administration for pulmonary diseases such as chronic bronchitis, cystic fibrosis, COVID-19 and community-acquired pneumonia. In this context, we encapsulated azithromycin in polycaprolactone nanoparticles functionalized with phospholipids rich in dipalmitoylphosphatidylcholine and further produced a fine powder formulation by spray drying with monohydrated lactose. Nanoparticles obtained by the emulsion/solvent diffusion-evaporation technique exhibited a mean hydrodynamic diameter around 195-228 nm with a narrow monomodal size distribution (PdI < 0.2). Nanoparticle dispersions were spray-dried at different inlet temperatures, atomizing air-flow, aspirator air flow, and feed rate, using lactose as a drying aid, resulting in a maximal process yield of 63% and an encapsulation efficiency of 83%. Excipients and the dry powder formulations were characterized in terms of morphology, chemical structure, thermal analyses and particle size by SEM, FTIR, DSC/TGA and laser light diffraction. The results indicated spherical particles with 90% at 4.06 µm or below, an adequate size for pulmonary delivery. Aerosolization performance in a NGI confirmed good aerodynamic properties. Microbiological assays showed that the formulation preserves AZM antimicrobial effect against <i>Staphylococcus aureus</i> and <i>Streptococcus</i> pneumoniae strains, with halos above 18 mm. In addition, no formulation-related cytotoxicity was observed against the human cell lines BEAS-2B (lung epithelial), HUVEC (endothelial) and HFF1 (fibroblasts). Overall, the approach described here allows the production of AZM-PCL nanoparticles incorporated into inhalable microparticles, enabling more efficient pulmonary therapy of lung infections.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"27 ","pages":"13635"},"PeriodicalIF":2.9,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11513329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expanding the eligibility criteria for drugs in Canada's time-limited health technology assessment and temporary drug access processes will further accelerate access to new medicines. 扩大加拿大有时限的卫生技术评估和临时药品使用程序中的药品资格标准,将进一步加快新药的使用。
IF 2.9 4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2024-10-08 eCollection Date: 2024-01-01 DOI: 10.3389/jpps.2024.13694
Allison Wills
{"title":"Expanding the eligibility criteria for drugs in Canada's time-limited health technology assessment and temporary drug access processes will further accelerate access to new medicines.","authors":"Allison Wills","doi":"10.3389/jpps.2024.13694","DOIUrl":"https://doi.org/10.3389/jpps.2024.13694","url":null,"abstract":"","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"27 ","pages":"13694"},"PeriodicalIF":2.9,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142512099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting ketone body metabolism to treat fatty liver disease. 针对酮体代谢治疗脂肪肝。
IF 2.9 4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI: 10.3389/jpps.2024.13375
Sora Kwon, Reshani Jeyaratnam, Kyoung-Han Kim
{"title":"Targeting ketone body metabolism to treat fatty liver disease.","authors":"Sora Kwon, Reshani Jeyaratnam, Kyoung-Han Kim","doi":"10.3389/jpps.2024.13375","DOIUrl":"https://doi.org/10.3389/jpps.2024.13375","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a metabolic disorder marked by excessive accumulation of lipids within the liver. If untreated, this condition can progress to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and ultimately, hepatocellular carcinoma (HCC). Given the liver's pivotal role in glucose and fatty acid metabolism, disruptions in these processes are commonly observed in MASLD. Ketone bodies, crucial energy metabolites primarily produced in the liver, are also closely related to the progression of MASLD. Recent studies have demonstrated that disrupted ketogenesis not only accompanies MASLD, but may also play a causal role in its development and progression. Moreover, activation of the ketogenic pathway has been suggested as a promising strategy for reducing excessive hepatic fat accumulation. This review focuses on the regulation of ketogenesis in MASLD, emphasizing the significance of dietary and pharmacological interventions as potential therapeutic approaches to treat fatty liver disease.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"27 ","pages":"13375"},"PeriodicalIF":2.9,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacometabolomics of sulfonylureas in patients with type 2 diabetes: a cross-sectional study. 2 型糖尿病患者服用磺脲类药物的药物代谢组学:一项横断面研究。
IF 2.9 4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2024-09-17 eCollection Date: 2024-01-01 DOI: 10.3389/jpps.2024.13305
Khaled Naja, Najeha Anwardeen, Sara S Bashraheel, Mohamed A Elrayess
{"title":"Pharmacometabolomics of sulfonylureas in patients with type 2 diabetes: a cross-sectional study.","authors":"Khaled Naja, Najeha Anwardeen, Sara S Bashraheel, Mohamed A Elrayess","doi":"10.3389/jpps.2024.13305","DOIUrl":"10.3389/jpps.2024.13305","url":null,"abstract":"<p><strong>Background: </strong>Sulfonylureas have been a longstanding pharmacotherapy in the management of type 2 diabetes, with potential benefits beyond glycemic control. Although sulfonylureas are effective, interindividual variability exists in drug response. Pharmacometabolomics is a potent method for elucidating variations in individual drug response. Identifying unique metabolites associated with treatment response can improve our ability to predict outcomes and optimize treatment strategies for individual patients. Our objective is to identify metabolic signatures associated with good and poor response to sulfonylureas, which could enhance our capability to anticipate treatment outcome.</p><p><strong>Methods: </strong>In this cross-sectional study, clinical and metabolomics data for 137 patients with type 2 diabetes who are taking sulfonylurea as a monotherapy or a combination therapy were obtained from Qatar Biobank. Patients were empirically categorized according to their glycosylated hemoglobin levels into poor and good responders to sulfonylureas. To examine variations in metabolic signatures between the two distinct groups, we have employed orthogonal partial least squares discriminant analysis and linear models while correcting for demographic confounders and metformin usage.</p><p><strong>Results: </strong>Good responders showed increased levels of acylcholines, gamma glutamyl amino acids, sphingomyelins, methionine, and a novel metabolite 6-bromotryptophan. Conversely, poor responders showed increased levels of metabolites of glucose metabolism and branched chain amino acid metabolites.</p><p><strong>Conclusion: </strong>The results of this study have the potential to empower our knowledge of variability in patient response to sulfonylureas, and carry significant implications for advancing precision medicine in type 2 diabetes management.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"27 ","pages":"13305"},"PeriodicalIF":2.9,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the rational prescription of linezolid, the prevalence of thrombocytopenia and major drug interactions in patients with cardiovascular diseases: are there any cautions? 评估利奈唑胺的合理处方、血小板减少的发生率以及心血管疾病患者的主要药物相互作用:是否有任何注意事项?
IF 2.9 4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2024-09-12 eCollection Date: 2024-01-01 DOI: 10.3389/jpps.2024.13343
Mehrnoush Dianatkhah, Hamed Salami, Rasool Soltani, Alireza Hosseini
{"title":"Evaluation of the rational prescription of linezolid, the prevalence of thrombocytopenia and major drug interactions in patients with cardiovascular diseases: are there any cautions?","authors":"Mehrnoush Dianatkhah, Hamed Salami, Rasool Soltani, Alireza Hosseini","doi":"10.3389/jpps.2024.13343","DOIUrl":"https://doi.org/10.3389/jpps.2024.13343","url":null,"abstract":"<p><p>The present study evaluated the rational prescription of linezolid, the prevalence of thrombocytopenia, and major drug interactions in patients with cardiovascular diseases. We conducted a retrospective cross-sectional study on linezolid-treated patients at Shahid Chamran Heart Hospital in Isfahan from March 21, 2021, to March 20, 2022. Our research involved 132 patients who received linezolid. We reported 43.18% of linezolid prescriptions as irrational. Linezolid-induced thrombocytopenia is more common than previous studies, with a prevalence of 47.9%. We found a significant relationship between thrombocytopenia and the concomitant use of aspirin. The duration of treatment was identified as predicting factor for linezolid-induced thrombocytopenia. Moreover, the prevalence of interactions in the X and D categories was determined. Serotonergic and catecholamine medications were associated with 56.1% and 47.7% medication interactions, respectively. Our study found a high prevalence of linezolid-induced thrombocytopenia among patients with cardiovascular diseases. Based on this study, physicians should focus more closely on prescribing linezolid to patients with cardiovascular diseases. In addition to following rational antibiotic use, this susceptible group is also at an elevated risk of side effects (thrombocytopenia) and medication interactions.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"27 ","pages":"13343"},"PeriodicalIF":2.9,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and efficacy of phosphodiesterase-5 (PDE-5) inhibitors in fetal growth restriction: a systematic literature review and meta-analysis. 磷酸二酯酶-5(PDE-5)抑制剂对胎儿生长受限的安全性和有效性:系统文献综述和荟萃分析。
IF 2.9 4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2024-08-15 eCollection Date: 2024-01-01 DOI: 10.3389/jpps.2024.13206
Ying Liu, Ella Man-Wai Un, Ying Bai, Man Keong Chan, Luo Xin Zeng, Sut Leng Lei, Junjun Li, Carolina Oi Lam Ung
{"title":"Safety and efficacy of phosphodiesterase-5 (PDE-5) inhibitors in fetal growth restriction: a systematic literature review and meta-analysis.","authors":"Ying Liu, Ella Man-Wai Un, Ying Bai, Man Keong Chan, Luo Xin Zeng, Sut Leng Lei, Junjun Li, Carolina Oi Lam Ung","doi":"10.3389/jpps.2024.13206","DOIUrl":"10.3389/jpps.2024.13206","url":null,"abstract":"<p><p><b>Introduction:</b> Fetal growth restriction (FGR) is associated with a higher risk of perinatal morbidity and mortality, as well as long-term health issues in newborns. Currently, there is no effective medicine for FGR. Phosphodiesterase-5 (PDE-5) inhibitors have been shown in pre-clinical studies to improve FGR. This study aimed to evaluate the latest evidence about the clinical outcomes and safety of PDE-5 inhibitors for the management of FGR. <b>Methods:</b> Eight databases (PubMed, Embase, Medline, Web of Science, Cochrane Library, Chinese National Knowledge Infrastructure, Chinese Biomedical Database and WangFang Database) were searched for English and Chinese articles published from the database inception to December 2023. Randomized controlled trials (RCTs) reporting the use of PDE-5 inhibitors in FGR were included. The quality of the RCTs was assessed using the Cochrane Risk of Bias Tool. Odds ratio and mean difference (MD) (95% confidence intervals) were pooled for meta-analysis. <b>Results:</b> From 253 retrieved publications, 16 studies involving 1,492 pregnant women met the inclusion criteria. Only sildenafil (15 RCTs) and tadalafil (1 RCT) were studied for FGR. Compared with the control group (placebo, no treatment, or other medication therapies), sildenafil increased birth weight, pregnancy prolongation and umbilical artery pulsatility indices. However, it also increased the risk of pulmonary hypertension in newborns, as well as headache and flushing/rash in mothers. There were no significant differences in gestation age, perinatal mortality or major neonatal morbidity, stillbirth, neonate death, infants admitted to neonatal intensive care unit, intraventricular hemorrhage and necrotizing enterocolitis in infants, as well as pregnancy hypertension and gastrointestinal side effects in mothers between the treatment and the control groups. <b>Discussion:</b> Sildenafil was the most investigated PDE-5 inhibitors for FGR. Current evidence suggests that sildenafil can improve birth weight and duration of pregnancy but at the same time increase the risk of neonatal pulmonary hypertension. It remains uncertain whether the benefits of sildenafil in FGR outweigh the risks and further high-quality RCTs are warranted. <b>Systematic Review Registration:</b> https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=325909.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"27 ","pages":"13206"},"PeriodicalIF":2.9,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11357966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Forkhead box O1 transcription factor; a therapeutic target for diabetic cardiomyopathy. 叉头盒 O1 转录因子;糖尿病心肌病的治疗靶点。
IF 2.9 4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2024-08-14 eCollection Date: 2024-01-01 DOI: 10.3389/jpps.2024.13193
Tanin Shafaati, Keshav Gopal
{"title":"Forkhead box O1 transcription factor; a therapeutic target for diabetic cardiomyopathy.","authors":"Tanin Shafaati, Keshav Gopal","doi":"10.3389/jpps.2024.13193","DOIUrl":"10.3389/jpps.2024.13193","url":null,"abstract":"<p><p>Cardiovascular disease including diabetic cardiomyopathy (DbCM) represents the leading cause of death in people with diabetes. DbCM is defined as ventricular dysfunction in the absence of underlying vascular diseases and/or hypertension. The known molecular mediators of DbCM are multifactorial, including but not limited to insulin resistance, altered energy metabolism, lipotoxicity, endothelial dysfunction, oxidative stress, apoptosis, and autophagy. FoxO1, a prominent member of forkhead box O transcription factors, is involved in regulating various cellular processes in different tissues. Altered FoxO1 expression and activity have been associated with cardiovascular diseases in diabetic subjects. Herein we provide an overview of the role of FoxO1 in various molecular mediators related to DbCM, such as altered energy metabolism, lipotoxicity, oxidative stress, and cell death. Furthermore, we provide valuable insights into its therapeutic potential by targeting these perturbations to alleviate cardiomyopathy in settings of type 1 and type 2 diabetes.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"27 ","pages":"13193"},"PeriodicalIF":2.9,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11349536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preparation, solubility, and anti-inflammatory effects of a complex of diphenylcyclopropenone/β-cyclodextrin derivatives as the treatment of alopecia areata. 二苯基环丙烯酮/β-环糊精衍生物复合物的制备、溶解性和抗炎作用,用于治疗斑秃。
IF 2.9 4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2024-08-13 eCollection Date: 2024-01-01 DOI: 10.3389/jpps.2024.13230
Yutaka Inoue, Kaede Yoshino, Suzu Kudo, Nao Kodama, Hajime Moteki, Mitsutoshi Kimura
{"title":"Preparation, solubility, and anti-inflammatory effects of a complex of diphenylcyclopropenone/β-cyclodextrin derivatives as the treatment of alopecia areata.","authors":"Yutaka Inoue, Kaede Yoshino, Suzu Kudo, Nao Kodama, Hajime Moteki, Mitsutoshi Kimura","doi":"10.3389/jpps.2024.13230","DOIUrl":"10.3389/jpps.2024.13230","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the preparation of inclusion complexes of diphenylcyclopropenone (DPCP)/β-cyclodextrin (β-CD) derivatives using a three-dimensional (3D) ball mill, and verify the inclusion behavior of the solid dispersion. Additionally, we aimed to investigate the effect of DPCP/β-CDs complex formation on the spleens of male C57BL/6 mice in terms of anti-inflammatory effects.</p><p><strong>Methods: </strong>The inclusion complexes of DPCP with β-CD and hydroxypropyl-β-cyclodextrin (HPβCD) were prepared using a 3D ball mill. Powder X-ray diffraction (PXRD) and Fourier-transform infrared spectroscopy (FT-IR) were used to evaluate the solid-state properties. The solubility of the prepared DPCP/β-CD and HPβCD complexes and the intermolecular interaction between DPCP and β-CD derivatives in solution were assessed using 1H nuclear magnetic resonance (NMR). Furthermore, the anti-inflammatory effects of DPCPs in the prepared DPCP/CD complexes were investigated using spleens from male C57BL/6 mice, with measurement of interferon gamma (IFN-γ) secretion as an endpoint. Additionally, the protective effects of each drug on NIH-3T3 cells exposed to ultraviolet (UV) irradiation were examined.</p><p><strong>Results: </strong>Solid-state characterization confirmed the formation of inclusion complexes in the 3D ground mixture (3DGM) (DPCP/β-CD = 1/1) and 3DGM (DPCP/HPβCD = 1/1) complexes through PXRD and IR analysis. The solubility of 3DGM (DPCP/β-CD = 1/1) and 3DGM (DPCP/HPβCD = 1/1) was 17.5 μg/mL and 58.4 μg/mL, respectively, indicating higher solubility than that of DPCP alone. NMR analysis of 3DGM samples suggested that DPCP/β-CD and DPCP/HPβCD form inclusion complexes at a molar ratio of 1/1 but with different inclusion modes. Regarding the anti-inflammatory activity of DPCP, 3DGM (DPCP/HPβ-CD) showed anti-inflammatory effects at lower doses compared to 3DGM (DPCP/β-CD) in terms of IFN-γ and NIH-3T3 cells injured by UV irradiation.</p><p><strong>Conclusion: </strong>We successfully formed inclusion complexes of DPCP/β-CD and DPCP/HPβCD using the 3D ground mixture method. NMR analysis suggested that DPCP/β-CD and DPCP/HPβCD form inclusion complexes at a molar ratio of 1/1 but with different inclusion modes. The anti-inflammatory activity of DPCP was more pronounced in 3DGM (DPCP/HPβCD) at lower doses compared to that in 3DGM (DPCP/β-CD), indicating that the HPβCD derivatives were more effective in enhancing the anti-inflammatory properties of DPCP.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"27 ","pages":"13230"},"PeriodicalIF":2.9,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of modular polymeric nanoparticles for drug delivery using amine reactive chemistry. 利用胺反应化学技术开发用于给药的模块化聚合物纳米颗粒。
IF 2.9 4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2024-08-06 eCollection Date: 2024-01-01 DOI: 10.3389/jpps.2024.13148
Calvin Wong, Emmanuel A Ho
{"title":"Development of modular polymeric nanoparticles for drug delivery using amine reactive chemistry.","authors":"Calvin Wong, Emmanuel A Ho","doi":"10.3389/jpps.2024.13148","DOIUrl":"10.3389/jpps.2024.13148","url":null,"abstract":"<p><p>Curcumin has been explored for its anti-cancer potential, but is severely limited by its hydrophobicity and sensitivity to light and water. In this study, poly (lactic-co-glycolic) acid (PLGA) nanoparticles (NPs) were synthesized to encapsulate curcumin via single emulsion method to improve curcumin stability and bioavailability. The PLGA NPs were coated with oligomeric chitosan (COS) and RGD peptide (a peptide consisting of Arg-Gly-Asp) using amine-reactive chemistry (NHS and EDC). Both COS and RGD had been previously shown to accumulate and target many different types of cancer cells. NPs were characterised based on size distribution, zeta potential, and binding efficiency of RGD peptide. They were also evaluated on encapsulation efficiency, and stability, of curcumin within the NPs. OVCAR-3 cancer cells were treated with COS and RGD-coated PLGA NPs loaded with Coumarin-6 dye for fluorescent imaging of cell uptake. They were also treated with curcumin-loaded NPs to determine cytotoxicity and effectiveness of delivery. The NPs exhibited size distribution and zeta potential within expected values, though binding efficiency of RGD was low. Curcumin-loaded NPs showed significant increase in cytotoxicity over free (unencapsulated) curcumin, and void (empty) NPs, suggesting successful delivery of curcumin as an anti-cancer agent; the performance of COS and RGD coated NPs over bare PLGA NPs was inconclusive, however, optimization will be required to improve formulation during the coating steps. This method of NP synthesis serves as proof of concept for a modular solution to the development of various coated polymeric NPs for other drugs or applications.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"27 ","pages":"13148"},"PeriodicalIF":2.9,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11333243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142009852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of branched-chain amino acids and their downstream metabolites in mediating insulin resistance. 支链氨基酸及其下游代谢物在介导胰岛素抵抗中的作用。
IF 2.9 4区 医学
Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2024-06-28 eCollection Date: 2024-01-01 DOI: 10.3389/jpps.2024.13040
Abdualrahman Mohammed Abdualkader, Qutuba G Karwi, Gary D Lopaschuk, Rami Al Batran
{"title":"The role of branched-chain amino acids and their downstream metabolites in mediating insulin resistance.","authors":"Abdualrahman Mohammed Abdualkader, Qutuba G Karwi, Gary D Lopaschuk, Rami Al Batran","doi":"10.3389/jpps.2024.13040","DOIUrl":"10.3389/jpps.2024.13040","url":null,"abstract":"<p><p>Elevated levels of circulating branched-chain amino acids (BCAAs) and their associated metabolites have been strongly linked to insulin resistance and type 2 diabetes. Despite extensive research, the precise mechanisms linking increased BCAA levels with these conditions remain elusive. In this review, we highlight the key organs involved in maintaining BCAA homeostasis and discuss how obesity and insulin resistance disrupt the intricate interplay among these organs, thus affecting BCAA balance. Additionally, we outline recent research shedding light on the impact of tissue-specific or systemic modulation of BCAA metabolism on circulating BCAA levels, their metabolites, and insulin sensitivity, while also identifying specific knowledge gaps and areas requiring further investigation. Finally, we summarize the effects of BCAA supplementation or restriction on obesity and insulin sensitivity.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":"27 ","pages":"13040"},"PeriodicalIF":2.9,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11239365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信